Tag: cancer research
Setback for Bristol Myers Squibb: CheckMate -73L trial fails to meet endpoint
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 CheckMate -73L trial did not achieve its primary endpoint of progression-free survival (PFS) in patients ... Read More
Innovent Biologics showcases promising preclinical data at AACR 2024
In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and ... Read More